Skip to main content
. 2018 Feb 14;91(1084):20170457. doi: 10.1259/bjr.20170457

Figure 3.

Figure 3.

A 52-year-old female with metastatic melanoma in a Phase 1 trial of MK-3475 (Pembrolizumab). Images 3a–c show the right upper lobe lung mass (shown with black arrow) at baseline, follow-up 1 (15 weeks after BL) and follow-up 6 (1 year after follow-up 1) respectively. Target right upper lobe lung mass shows slow response to treatment. BL, baseline.